Time for process excellence in Pharma R&D?
For years pharmaceutical companies could rake in high margins on drugs that were protected by patents. But as many patents have expired or are near expiration – so much so that the industry is calling it the "patent cliff" – pharma companies are having to look much harder at how they can streamline processes in R&D to save time and money.
In this Process Perspectives podcast, Andrew Parson, VP Preclinical Drug Development at GlaxoSmithKline and Gerald Fincken, CEO of CSM Clinical...
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.